Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Slowdown From Bayer On Business Development Front

Since 2015, Invested $1.7bn In Over 55 Start-ups

Executive Summary

“We're looking at opportunities almost on a weekly basis,” Bayer’s pharma chief Stefan Oelrich told Scrip as the German major posted a solid set of financials for the fourth quarter.

You may also be interested in...



Bayer Sharpens US Focus As Pressure Tightens On Drug Makers

The German company’s two top sellers are marketed by partners in the US, but Bayer will pocket all US sales from its four newest products, at a time when pressures are mounting at home and abroad.

Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors

All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.

Bayer May Not Launch In Innovation-Unfriendly European Markets

The attractiveness of investing in R&D and launching new products in Europe is wearing off, especially when compared with the US marketplace, Bayer pharma head Stefan Oelrich tells Scrip.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel